Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market In 2029?

In recent years, the cardiology and neurology in-vitro diagnostic (IVD) market has seen substantial growth. This growth will rise from $15.84 billion in 2024 to $17.27 billion in 2025, representing a compound annual growth rate (CAGR) of 9.0%. The increase in the historical period can be credited to the growing occurrence of age-related cardiovascular and neurological disorders, an aging population, a boosted focus on preventative health care and early disease detection, and the increasing burden of cardiovascular diseases (CVDs) and neurological disorders such as stroke and Alzheimer’s disease. Additionally, augmenting investments in healthcare infrastructure and enhanced regulatory frameworks supporting the approval and reimbursement of diagnostic tests have largely contributed to the market growth.

What Growth Rate Is Forecasted for the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market by 2029?

Expectations indicate a robust expansion in the in vitro diagnostic (IVD) market for cardiology and neurology. This growth should position the market at approximately $24.07 billion by 2029, with an 8.7% compound annual growth rate (CAGR). This anticipated expansion in the forecasted timeline arises from the shift towards personalized medicine in the fields of cardiology and neurology. There’s also increased demand for swift, on-the-spot test solutions in these areas, remote consultation and telemedicine growth, and a rise in research projects. Key trends for this period include the rise of liquid biopsy technologies, improvements in nanotechnology, uptake of remote monitoring devices like implantable cardiac monitors and brain-computer interfaces, utilization of multiplex biomarker panels, advancements in medical imaging techniques like MRI, CT, and PET scans, and creation of companion diagnostics for cardiovascular and neurological medication.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15829&type=smp

Which Key Companies Are Shaping the Future of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

Major companies operating in the in vitro diagnostic (IVD) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience

Which Factors Are Driving Demand in the In Vitro Diagnostic (IVD) In Cardiology And Neurology Industry?

The proliferation of personalised healthcare is anticipated to propel the expansion of the cardiology and neurology in vitro diagnostic (IVD) market. This medical route personalises healthcare decisions, practices, treatments, and interventions to suit every individual’s unique traits. A surge in genomics, better comprehension of disease processes, demand from patients for custom treatments, and backing from regulatory bodies are some of the reasons for the continued growth of personalised healthcare. In vitro diagnostic (IVD) testing in cardiology and neurology augments personalised healthcare by providing vital information about an individual’s genetic composition and disease state, thus helping to shape custom treatment plans for enhanced effectiveness and minimised risks. For example, in 2022, 12 recently approved personalised medicines accounted for nearly 34% of all newly approved treatments, according to the Personalized Medicine Coalition, an American professional membership body. This indicated a significant increase from earlier years. Hence, the escalating number of personalised medicines is fuelling the growth of the cardiology and neurology in vitro diagnostic (IVD) market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15829&type=smp

How Is the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Segmented by Several Divisions?

The in vitro diagnostic (IVD) in cardiology and neurology market covered in this report is segmented –

1) By Product Type: Instruments, Reagents And Consumables, Software And Services

2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies

3) By End-User: Hospitals, Clinical Laboratories, Other End-Users

Subsegments:

1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices, Electrophysiology Devices

2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables

3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services

What are the Emerging Market Trends Driving the Growth of the In Vitro Diagnostic (IVD) In Cardiology And Neurology Industry?

Leading firms in the in vitro diagnostic (IVD) space for cardiology and neurology are turning to AI-powered integrated epigenetic systems for the early identification and evaluation of diseases. These systems take advantage of advanced machine learning models and biomarker assessment processes to improve both the sensitivity and precision of diagnoses and monitoring for heart diseases, effectively addressing key factors leading to disease advancement. For example, in February 2023, US-based biotech firm Cardio Diagnostics Holdings Inc. introduced PrecisionCHD, an AI-powered blood test for the early diagnosis of coronary heart disease (CHD). The test uses the company’s unique integrated epigenetic-genetic engine to gauge CHD risk with the goal of preventing and detecting the most widespread form of heart disease. This innovative test blends epigenetic and genetic biomarkers with machine learning algorithms, boasting over 75% accuracy in both males and females. It correlates a patient’s biomarker profile with alterable risk factors, significant causes of CHD like smoking, diabetes, hypertension, and elevated cholesterol levels. PrecisionCHD provides a non-invasive substitute for exercise stress tests or angiograms, requiring only blood samples that can be collected either in a doctor’s office or at the patient’s home.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostic-ivd-in-cardiology-and-neurology-global-market-report

Which Regions Are Driving Growth in the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (IVD) in cardiology and neurology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15829

This Report Delivers Insight On:

1. How big is the in vitro diagnostic (ivd) in cardiology and neurology market, and how is it changing globally?

2. Who are the major companies in the in vitro diagnostic (ivd) in cardiology and neurology market, and how are they performing?

3. What are the key opportunities and risks in the in vitro diagnostic (ivd) in cardiology and neurology market right now?

4. Which products or customer segments are growing the most in the in vitro diagnostic (ivd) in cardiology and neurology market?

5. What factors are helping or slowing down the growth of the in vitro diagnostic (ivd) in cardiology and neurology market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model